AU2008223066A1 - Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders - Google Patents

Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders Download PDF

Info

Publication number
AU2008223066A1
AU2008223066A1 AU2008223066A AU2008223066A AU2008223066A1 AU 2008223066 A1 AU2008223066 A1 AU 2008223066A1 AU 2008223066 A AU2008223066 A AU 2008223066A AU 2008223066 A AU2008223066 A AU 2008223066A AU 2008223066 A1 AU2008223066 A1 AU 2008223066A1
Authority
AU
Australia
Prior art keywords
compound
mwo1
substituted
alkyl
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2008223066A
Other languages
English (en)
Inventor
Linda J. Van Eldik
Mark S. Wainwright
D. Martin Watterson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of AU2008223066A1 publication Critical patent/AU2008223066A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008223066A 2007-03-02 2008-02-29 Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders Abandoned AU2008223066A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90460607P 2007-03-02 2007-03-02
US60/904,606 2007-03-02
US438507P 2007-11-27 2007-11-27
US60/004,385 2007-11-27
PCT/US2008/055495 WO2008109437A2 (en) 2007-03-02 2008-02-29 Compositions and treatments for seizure-related disorders

Publications (1)

Publication Number Publication Date
AU2008223066A1 true AU2008223066A1 (en) 2008-09-12

Family

ID=39345468

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008223066A Abandoned AU2008223066A1 (en) 2007-03-02 2008-02-29 Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders

Country Status (5)

Country Link
EP (1) EP2131839A2 (enExample)
JP (1) JP2010520223A (enExample)
AU (1) AU2008223066A1 (enExample)
CA (1) CA2679917A1 (enExample)
WO (1) WO2008109437A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018563A1 (en) 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
EP2592075B1 (en) 2004-11-02 2015-04-29 Northwestern University Pyridazine compounds for the treatment of inflammatory diseases
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EA201170624A1 (ru) 2008-10-30 2011-12-30 Мерк Шарп Энд Домэ Корп. Изоникотинамидные антагонисты рецепторов орексинов
JP2012507540A (ja) 2008-10-30 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3217325A1 (de) * 1982-05-08 1983-11-10 Hoechst Ag, 6230 Frankfurt 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
WO2003018563A1 (en) * 2001-08-31 2003-03-06 Northwestern University Anti-inflammatory and protein kinase inhibitor composition and method of use
EP2015751A2 (en) * 2006-04-28 2009-01-21 Northwestern University Salts of pyridazine compounds

Also Published As

Publication number Publication date
CA2679917A1 (en) 2008-09-12
WO2008109437A3 (en) 2009-11-19
EP2131839A2 (en) 2009-12-16
WO2008109437A2 (en) 2008-09-12
JP2010520223A (ja) 2010-06-10

Similar Documents

Publication Publication Date Title
US8158627B2 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AU2008223066A1 (en) Compositions comprising derivatives of 3 -phenylpyridazine for treating seizure-related disorders
US8933076B2 (en) Pyridazine compounds, compositions and methods
US20100292157A1 (en) Combination Treatments for Alzheimer's Disease and Similar Diseases
US20100168120A1 (en) Salts of pyridazine compounds
JP2009535344A (ja) 神経炎症性疾患の処置のためのピリダジン化合物を含む処方物
WO2007127475A2 (en) Pyridazines for demyelinating diseases and neuropathic pain
WO2007130383A2 (en) Compositions and treatments using pyridazine compounds and secretases
US20100173960A1 (en) The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20100210590A1 (en) Compositions and treatments for seizure-related disorders
CA3047836A1 (en) Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions
CA2589102C (en) Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
US20110105626A1 (en) Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
US20100331267A1 (en) Use of cyclohexanehexol derivatives in the treatment of alpha-synucleinopathies
US20100144891A1 (en) Use of cyclohexanehexol derivatives in the treatment of amyotrophic lateral sclerosis
KR20110083324A (ko) 비타민 ｃ를 포함하는 태아의 신경세포 보호용 조성물

Legal Events

Date Code Title Description
MK3 Application lapsed section 142(2)(c) - examination deferred under section 46 no request for examination